Stockscreener 앱 받기
84.75
0.35%
-0.286
Astrazeneca PLC 주식(AZN)의 최신 뉴스
AstraZeneca Is Said to Reach Landmark Drug Price Deal With Trump - Bloomberg.com
Trump said to unveil deal with AstraZeneca today - breakingthenews.net
Trump strikes drug-pricing deal with pharma giant AstraZenecaMSNBC - MarketScreener
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
AZN: AstraZeneca Among Companies Watching TrumpRx Developments - GuruFocus
AstraZeneca increases scope of new US API manufacturing facility by $500m - MarketScreener
Saudi Arabia Adult Vaccine Market Forecast Report 2025-2033 Featuring Company Analysis and Vaccine Sales of GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, CSL LimitedResearchAndMarkets.com - Business Wire
AstraZeneca sets $4.5bn Virginia API plant construction in motion - Pharmaceutical Technology
Turbine and AstraZeneca partner for ADC discovery - Pharmaceutical Technology
AstraZeneca: $4.5bn investment in Virginia - MarketScreener
Volume spikes in AstraZeneca PLC Depositary Receipt stock – what they meanDollar Strength & High Conviction Investment Ideas - newser.com
AstraZeneca Lifts US Plant Investment to $4.5 Billion to Boost Drug Manufacturing - MarketScreener
AstraZeneca to Invest $4.5 Billion in New US Manufacturing Facility - MarketScreener
AstraZeneca breaks ground on enormous $4.5bn Virginia manufacturing plant - BioProcess International
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity DrugsAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca boosts investment in Virginia plant (AZN:NASDAQ) - Seeking Alpha
AstraZeneca to invest $4.5 billion in Virginia manufacturing facility By Investing.com - Investing.com South Africa
AstraZeneca to invest $4.5B in Virginia facility - breakingthenews.net
AstraZeneca ups investment at new Virginia facility to USD4.5 billion - MarketScreener
AstraZeneca to Boost Spending on Virginia Plant by $500 Million to $4.5 Billion - MarketScreener
AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boos - GuruFocus
AstraZeneca to increase investment & scope of Virginia manufacturing facility to $4.5 bln - MarketScreener
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - MarketScreener
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs - MarketScreener
3,600 Jobs: AstraZeneca Expands Virginia Investment to $4.5B, Adds ADC Cancer Manufacturing - Stock Titan
Turbine Launches Collaboration with Astrazeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
What machine learning models say about AstraZeneca PLC Depositary ReceiptWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
AstraZeneca (LSE:AZN) Developments Within FTSE 100 and FTSE 350 Healthcare - Kalkine Media
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Dru - GuruFocus
Algen inks $555m AstraZeneca partnership for AI-powered drug discovery - BioXconomy
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary Receipt2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Will AstraZeneca PLC Depositary Receipt bounce back from current supportEarnings Risk Report & High Yield Stock Recommendations - newser.com
AstraZeneca PLC $AZN Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN
AstraZeneca PLC Depositary Receipt recovery potential after sell off2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com
AstraZeneca PLC Depositary Receipt stock momentum explained2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Stock of the Week: Is AstraZeneca a Buy After Share Price Jump? - Morningstar Canada
Barclays Keeps AstraZeneca at Overweight, Expects 'Resilient' Q3 Results - MarketScreener
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
What AstraZeneca Can Teach Us About Scaling Innovation Through Ecosystem Collaboration - MarketScreener
AstraZeneca Shares Surge 14% as Investment Pause Spurs Fresh Valuation Debate - Yahoo
Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock - sharewise.com
AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension - Benzinga
Another Baxdrostat Success Takes Pressure Off AstraZeneca - insights.citeline.com
AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension - MarketScreener
AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher - Yahoo Finance
AstraZeneca PLC $AZN Stock Holdings Lowered by Meitav Investment House Ltd. - MarketBeat
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
AstraZeneca Reports Positive Bax24 Trial Results for Hypertension - AskTraders.com
AstraZeneca Says Phase 3 Trial of Baxdrostat Meets Endpoint in Resistant Hypertension - MarketScreener
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
AstraZeneca reports Phase III trial success for baxdrostat in hypertension - Investing.com
AstraZeneca PLC Announces Baxdrostat Demonstrates A Statistically Significant and Highly clinically meaningful Reduction in 24-Hour Systolic Blood Pressure Compared with Placebo - MarketScreener
AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial - MarketScreener
AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer - Clinical Trials Arena
D.B. Root & Company LLC Cuts Stake in AstraZeneca PLC $AZN - MarketBeat
BreakingviewsAstraZeneca’s New York shift augurs London exodus - Reuters
AstraZeneca blood pressure drug succeeds in late-stage trial - Financial Times
AstraZeneka presents results for patients with resistant hypertension - MarketScreener
Barclays Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $187.71 - 富途牛牛
AstraZeneca’s experimental hypertension drug shows promising results - Investing.com
AstraZeneca’s baxdrostat hits key goal in major blood pressure trial - Proactive financial news
AstraZeneca says baxdrostat met primary endpoint in BAX24 Ph3 trial - MarketScreener
AstraZeneca : Baxdrostat met primary endpoint in Bax24 Ph3 trial - MarketScreener
REGAstraZeneca PLCBaxdrostat met primary endpoint in Bax24 Ph3 trial - TradingView
자본화:
|
볼륨(24시간):